Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Friday, June 27th. The stock was sold at an average price of $20.91, for a total transaction of $67,957.50. Following the transaction, the chief financial officer directly owned 23,000 shares in the company, valued at approximately $480,930. This represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Tuesday, May 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.18, for a total transaction of $52,585.00.
• On Monday, April 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.69, for a total value of $60,742.50.

Enliven Therapeutics Stock Up 0.2%

Shares of ELVN traded up $0.04 during mid-day trading on Thursday, hitting $20.68. 272,507 shares of the company's stock traded hands, compared to its average volume of 296,341. The business's 50-day moving average price is $19.49 and its 200-day moving average price is $20.40. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The firm has a market capitalization of $1.01 billion, a P/E ratio of -10.77 and a beta of 0.83.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ELVN. Invesco Ltd. grew its stake in Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company's stock worth $339,000 after purchasing an additional 508 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enliven Therapeutics by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock worth $451,000 after buying an additional 718 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock worth $489,000 after acquiring an additional 1,285 shares in the last quarter. Finally, California State Teachers Retirement System lifted its position in Enliven Therapeutics by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 20,914 shares of the company's stock valued at $471,000 after acquiring an additional 1,940 shares during the period. Institutional investors own 95.08% of the company's stock.

Analysts Set New Price Targets

ELVN has been the subject of a number of recent analyst reports. Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 price target on the stock. Robert W. Baird upped their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Finally, HC Wainwright boosted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.